Topical brimonidine to reduce post-inflammatory response after IPL- treatment and effect on IPL-efficacy in patients with facial telangiectasias - Topical brimonidine to reduce post-inflammatory response after IPL- treatment and effect on IPL-effi

Bispebjerg Hospital0 个研究点目标入组 20 人开始时间: 2015年12月8日最近更新: 2017年12月11日

适应症

试验速览

暂无简介。

•Patients with moderate to severe facial telangiectasias referred to laser or IPL-treatment. Severity and distribution of telangiectasias must
•be symmetrical between left and right side of the face in the individual patient
•Telangiectasias may be observed in connection with rosacea, but rosacea must not demonstrate clinical active inflammation or acne
•18-65 years of age
•Fitzpatrick skin type I-III
•Fertile women must document non-reactive urine pregnancy test at the day of inclusion
•During the study, fertile women must be using effective birth control.Effective contraception is defined as follows:
•o Hormonal contraceptive (contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release) o Intrauterine device;
•o Trans-abdominal surgical sterilization;
•o Sterilization implant device;
•o Surgical sterilization of male partner (given that the subject is monogamaous);
•Verbal and written consent to participate in the study
•Documentation of medicine status
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Clinical active dermatological disease in the face
•Wounds, dermatitis, tattoos or scars in treatment area
•Allergies to ingredients in Mirvaso
•Current treatment with monoamine oxidase inhibitors, tricyclic or tetracyclic antidepressants which interacts with the noradrenergic transmission
•Current treatment with other systemic adrenergic receptor agonists or antagonists
•Patients with known liver or renal disease
•UV-exposure (solarium or sunbathing) or other treatment within the last month that enhances skin pigmentation
•Use of other topical agents that may interact with treatment
•Local or systemic treatment with photosensitizing drugs
•Pregnancy and breastfeeding women
•Current participation in other clinical trials
•Patients that are considered incapable of complying with the protocol, i.e. patients suffering from dementia, alcoholism or psychiatric conditions

发起方